Oral Delivery of Novel Recombinant Lactobacillus Elicit High Protection against Staphylococcus aureus Pulmonary and Skin Infections

Staphylococcus aureus is a leading cause of nosocomial and community-associated infection worldwide; however, there no licensed vaccine available. S. initiates via the mucosa; therefore, mucosal likely to be promising approach against infection. Lactobacilli, non-pathogenic bacterium, has gained increasing interest as delivery vehicle. Hence, we attempted develop an oral based on lactobacilli cushion stress drug resistance needs. In this study, designed, constructed, evaluated recombinant Lactobacillus strains synthesizing nontoxic mutated ?-hemolysins (HlaH35L). The results from animal clinical trials showed that can persist for at least 72 h stably express heterologous protein in vivo. Recombinant L. plantarum WXD234 (pNZ8148-Hla) could induce robust immunity GALT, evidenced by significant increase IgA IL-17 production strong proliferation T-lymphocytes derived Peyer’s patches. conferred up 83% protection pulmonary significantly reduced abscess size skin model. Of particular sharp reduction protective effect offered vaccination ?? T cell-deficient or IL-17-deficient mice. conclusion, first time, genetically engineered induced superior immunity, which was associated with high infections caused aureus. Taken together, our findings suggest great potential system provide experimental data development vaccines